Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
content:opsoclonus_myoclonus_ataxia_syndrome [2024/03/12 08:59] – biju.hameed@gmail.com | content:opsoclonus_myoclonus_ataxia_syndrome [2024/03/15 19:11] (current) – biju.hameed@gmail.com | ||
---|---|---|---|
Line 1: | Line 1: | ||
+ | ====== Opsoclonus Myoclonus Ataxia Syndrome ====== | ||
+ | {{page> | ||
^ Recommendations for the Dosing and Monitoring of Immunotherapeutic Agents in the Treatment of OMAS: Steroid Treatment and Ivig || | ^ Recommendations for the Dosing and Monitoring of Immunotherapeutic Agents in the Treatment of OMAS: Steroid Treatment and Ivig || | ||
| **Treatment of OMS in children** | | **Treatment of OMS in children** | ||
Line 6: | Line 8: | ||
| Regimen | | Regimen | ||
| | Pulsed dexamethasone has been widely used as first-line steroid treatment. This may be given as: | | | | Pulsed dexamethasone has been widely used as first-line steroid treatment. This may be given as: | | ||
- | | | + | | |20 mg/ |
| |12 pulses at 3 to 4 weekly intervals | | |12 pulses at 3 to 4 weekly intervals | ||
| | The scheduled 12 pulses of dexamethasone should always be completed, even with earlier complete remission. | | | The scheduled 12 pulses of dexamethasone should always be completed, even with earlier complete remission. |